Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Peripheral Neuropathic Pain.

Inclusion criteria: * 18 years old and above, male or female * Diagnosed by trained clinical doctors as postherpetic neuralgia, which is an indication for peripheral nerve stimulation therapy; * Assess the damage or disease of the peripheral sensory system through the four questions of Douleur Neuropathy before surgery; * The subject has received conventional treatment but the efficacy is poor, or cannot tolerate the side effects of conventional treatment; * Visual analogue scale for pain within 24 hours before surgery ≥ 5; * The subjects are able to understand the purpose of this study, have sufficient compliance with the research treatment, and are willing to sign an informed consent form; Exclusion criteria: * Subjects who need to receive both radio frequency modulation and intrathecal drug infusion treatment simultaneously; * Subjects who are known to have cardiac implants (pacemakers or defibrillators) or other implantable neural stimulators (spinal cord stimulators or deep brain stimulators, etc.); * Subjects with severe psychological and/or mental disorders and/or non therapeutic drug dependence; * Subjects expected to undergo MRI examination within 30 days after PNS implantation; * Expected to be discharged within 48 hours or less; * Target nerve damage or muscle defects in known pain areas; * Subjects who are known to be allergic to skin contact materials (tape or adhesive); * Allergy to anesthetics such as lidocaine; * Concomitant severe heart disease, liver disease, kidney disease, respiratory system disease, and coagulation dysfunction; * Pregnant women, lactating women, or women planning to have children within the next three months; * Subjects who have participated in any other clinical trial, or who may participate in any other trial after enrollment; * Other situations that the researcher deems unsuitable for participation in this clinical trial